Reference(s)
Click here to return to the Reference Table

Cancer type: Liver


HGF/SF expression

Reference Number: 70
Bilezikci, B., Haberal, A. N. & Demirhan, B. Hepatocyte growth factor in patients with three different stages of chronic liver disease including hepatocellular carcinoma, cirrhosis and chronic hepatitis: an immunohistochemical study. Can J Gastroenterol 15, 159-65 (2001).
PubMed link      E-mail link

Reference Number: 71
Guirouilh, J. et al. Expression of hepatocyte growth factor in human hepatocellular carcinoma. J Hepatol 34, 78-83 (2001).
PubMed link      E-mail link

Reference Number: 72
Kiss, A., Wang, N. J., Xie, J. P. & Thorgeirsson, S. S. Analysis of transforming growth factor (TGF)-alpha/epidermal growth factor receptor, hepatocyte growth Factor/c-met,TGF-beta receptor type II, and p53 expression in human hepatocellular carcinomas. Clin Cancer Res 3, 1059-66 (1997).
PubMed link      E-mail link

Reference Number: 73
Ljubimova, J. Y., Petrovic, L. M., Wilson, S. E., Geller, S. A. & Demetriou, A. A. Expression of HGF, its receptor c-met, c-myc, and albumin in cirrhotic and neoplastic human liver tissue. J Histochem Cytochem 45, 79-87 (1997).
PubMed link      E-mail link

Reference Number: 74
Schoedel, K. E., Tyner, V. Z., Kim, T. H., Michalopoulos, G. K. & Mars, W. M. HGF, MET, and Matrix-Related Proteases in Hepatocellular Carcinoma, Fibrolamellar Variant, Cirrhotic and Normal Liver. Mod Pathol 16, 14-21 (2003).
PubMed link      E-mail link

Reference Number: 450
Osada S, Kanematsu M, Imai H, Goshima S, Sugiyama Y. Evaluation of extracellular signal regulated kinase expression and its relation to treatment of hepatocellular carcinoma. J Am Coll Surg. 201, 405-11 (2005)
PubMed link      E-mail link

Reference Number: 468
Yang H, Magilnick N, Noureddin M, Mato JM, Lu SC. Effect of hepatocyte growth factor on methionine adenosyltransferase genes and growth is cell density-dependent in HepG2 cells. J Cell Physiol. 210, 766-73 (2007)
PubMed link      E-mail link

Reference Number: 474
Nakanishi C, Moriuchi A, Ido A, Numata M, Kim ID, Kusumoto K, Hasuike S, Abe H, Nagata K, Akiyama Y, Uto H, Kataoka H, Tsubouchi H. Effect of hepatocyte growth factor on endogenous hepatocarcinogenesis in rats fed a choline-deficient L-amino acid-defined diet. Oncol Rep. 16 25-31 (2006)
PubMed link      E-mail link

Reference Number: 477
Wu F, Wu L, Zheng S, Ding W, Teng L, Wang Z, Ma Z, Zhao W. The clinical value of hepatocyte growth factor and its receptor--c-met for liver cancer patients with hepatectomy. Dig Liver Dis. 38, 490-7 (2006)
PubMed link      E-mail link

Reference Number: 478
Lasagna N, Fantappie O, Solazzo M, Morbidelli L, Marchetti S, Cipriani G, Ziche M, Mazzanti R. Hepatocyte growth factor and inducible nitric oxide synthase are involved in multidrug resistance-induced angiogenesis in hepatocellular carcinoma cell lines. Cancer Res. 66, 2673-82 (2006)
PubMed link      E-mail link

Reference Number: 566
Hu RH, Ho MC, Wu YM, Lee PH. Peritoneal fluid contains high concentration of hepatocyte growth factor and vascular endothelial growth factor after resection for hepatocellular carcinoma. Hepatogastroenterology. 54, 862-5 (2007)
PubMed link      E-mail link

Reference Number: 573
Isbert C, Ritz JP, Roggan A, Schuppan D, Ajubi N, Buhr HJ, Hohenberger W, Germer CT. Laser-induced thermotherapy (LITT) elevates mRNA expression of connective tissue growth factor (CTGF) associated with reduced tumor growth of liver metastases compared to hepatic resection. Lasers Surg Med. 39, 42-50 (2007)
PubMed link      E-mail link

Reference Number: 589
Kopitz C, Gerg M, Bandapalli OR, Ister D, Pennington CJ, Hauser S, Flechsig C, Krell HW, Antolovic D, Brew K, Nagase H, Stangl M, von Weyhern CW, Brücher BL, Brand K, Coussens LM, Edwards DR, Krüger A. Tissue inhibitor of metalloproteinases-1 promotes liver metastasis by induction of hepatocyte growth factor signaling. Cancer Res. 67, 8615-23 (2007)
PubMed link      E-mail link

Reference Number: 632
Takami T, Kaposi-Novak P, Uchida K, Gomez-Quiroz LE, Conner EA, Factor VM, Thorgeirsson SS. Loss of hepatocyte growth factor/c-Met signaling pathway accelerates early stages of N-nitrosodiethylamine induced hepatocarcinogenesis. Cancer Res. 67, 9844-51 (2007)
PubMed link      E-mail link

Reference Number: 645
Lee KH, Choi EY, Hyun MS, Jang BI, Kim TN, Lee HJ, Eun JY, Kim HG, Yoon SS, Lee DS, Kim JH, Kim JR. Role of hepatocyte growth factor/c-Met signaling in regulating urokinase plasminogen activator on invasiveness in human hepatocellular carcinoma: a potential therapeutic target. Clin Exp Metastasis. 25, 89-96 (2008)
PubMed link      E-mail link

Reference Number: 659
Shirako E, Hirayama N, Tsukada Y, Tanaka T, Kitamura N. Up-regulation of p21CIP1 expression mediated by ERK-dependent and -independent pathways contributes to hepatocyte growth factor-induced inhibition of HepG2 hepatoma cell proliferation. J Cell Biochem. 104, 176-88 (2008)
PubMed link      E-mail link

Reference Number: 662
Sagmeister S, Eisenbauer M, Pirker C, Mohr T, Holzmann K, Zwickl H, Bichler C, Kandioler D, Wrba F, Mikulits W, Gerner C, Shehata M, Majdic O, Streubel B, Berger W, Micksche M, Zatloukal K, Schulte-Hermann R, Grasl-Kraupp B. New cellular tools reveal complex epithelial-mesenchymal interactions in hepatocarcinogenesis. Br J Cancer. 99, 151-9 (2008)
PubMed link      E-mail link

Reference Number: 665
Rui C, Li C, Xu W, Zhan Y, Li Y, Yang X. Involvement of Egr-1 in HGF-induced elevation of the human 5alpha-R1 gene in human hepatocellular carcinoma cells. Biochem J. 411, 379-86 (2008)
PubMed link      E-mail link

Reference Number: 681
Chau GY, Lui WY, Chi CW, Chau YP, Li AF, Kao HL, Wu CW. Significance of serum hepatocyte growth factor levels in patients with hepatocellular carcinoma undergoing hepatic resection. Eur J Surg Oncol. 34, 333-8 (2008)
PubMed link      E-mail link

Reference Number: 701
Abdel Aziz MT, El-Miligy D, Amin MA, El Ansari A, Ahmed HH, Marzouk S, Sabry D. Molecular evaluation of apoptotic versus antiapoptotic angiogenic markers in hepatocellular carcinoma. Clin Biochem41, 1008-14 (2008) Epub 2008 Feb 21
PubMed link      E-mail link

Reference Number: 722
Justinger C, Schlüter C, Oliviera-Frick V, Kopp B, Rubie C, Schilling MK. Increased growth factor expression after hepatic and pancreatic resection. Oncol Rep. 20, 1527-31 (2008)
PubMed link      E-mail link

Reference Number: 852
Piscaglia AC, Shupe TD, Pani G, Tesori V, Gasbarrini A, Petersen BE. Establishment of cancer cell lines from rat hepatocholangiocarcinoma and assessment of the role of granulocyte-colony stimulating factor and hepatocyte growth factor in their growth, motility and survival. J Hepatol. 51, 77-92 (2009)
PubMed link      E-mail link

Reference Number: 902
Wang Z, Ge L, Wang M, Carr BI. Grb2-associated binder-1 plays a central role in the hepatocyte growth factor enhancement of hepatoma growth inhibition by K vitamin analog compound 5. Hepatology. 46, 2003-13 (2007)
PubMed link      E-mail link

Reference Number: 904
Lee KH, Kim JR. Hepatocyte growth factor induced up-regulations of VEGF through Egr-1 in hepatocellular carcinoma cells. Clin Exp Metastasis. 26, 685-92 (2009)
PubMed link      E-mail link

Reference Number: 906
Grotegut S, Kappler R, Tarimoradi S, Lehembre F, Christofori G, Von Schweinitz D. Hepatocyte growth factor protects hepatoblastoma cells from chemotherapy-induced apoptosis by AKT activation. Int J Oncol. 36, 1261-7 (2010)
PubMed link      E-mail link

Reference Number: 908
Mu Z, Wang H, Zhang J, Li Q, Wang L, Guo X. KAI1/CD82 suppresses hepatocyte growth factor-induced migration of hepatoma cells via upregulation of Sprouty2. Sci China C Life Sci. 51, 648-54 (2008)
PubMed link      E-mail link

Reference Number: 938
Schrötzlmair F, Kopitz C, Halbgewachs B, Lu F, Algül H, Brünner N, Gänsbacher B, Krüger A. Tissue inhibitor of metalloproteinases-1-induced scattered liver metastasis is mediated by host-derived urokinase-type plasminogen activator. J Cell Mol Med. 14, 2760-70 (2010)
PubMed link      E-mail link

Reference Number: 946
Kubo E, Yoshikawa N, Kunitomo M, Kagota S, Shinozuka K, Nakamura K. Inhibitory effect of Cordyceps sinensis on experimental hepatic metastasis of melanoma by suppressing tumor cell invasion. Anticancer Res. 30, 3429-33 (2010)
PubMed link      E-mail link

Reference Number: 1026
Gu K, Lai ST, Ma NY, Zhao JD, Ren ZG, Wang J, Liu J, Jiang GL. Hepatic regeneration after sublethal partial liver irradiation in cirrhotic rats. J Radiat Res. 52, 582-91 (2011)
PubMed link      E-mail link

Reference Number: 1161
Wang YC, Xu GL, Jia WD, Han SJ, Ren WH, Wang W, Liu WB, Zhang CH, Chen H. Estrogen suppresses metastasis in rat hepatocellular carcinoma through decreasing interleukin-6 and hepatocyte growth factor expression. Inflammation. 35, 143-9 (2012)
PubMed link      E-mail link

Reference Number: 1200
Huang FI, Chen YL, Chang CN, Yuan RH, Jeng YM. Hepatocyte growth factor activates Wnt pathway by transcriptional activation of LEF1 to facilitate tumor invasion. Carcinogenesis. 33, 1142-8 (2012)
PubMed link      E-mail link

Reference Number: 1368
Ang CS, Sun MY, Huitzil-Melendez DF, Chou JF, Capanu M, Jarnagin W, Fong Y, Dematteo RP, D'Angelica M, Allen P, Chen CT, O'Reilly EM, Weiser MR, Abou-Alfa GK. c-MET and HGF mRNA expression in hepatocellular carcinoma: correlation with clinicopathological features and survival. Anticancer Res. 33, 3241-5 (2013)
PubMed link      E-mail link

Reference Number: 1385
Liu XL, Li FQ, Liu LX, Li B, Zhou ZP. TNF-a, HGF and macrophage in peritumoural liver tissue relate to major risk factors of HCC Recurrence. Hepatogastroenterology. 60, 1121-6 (2013)
PubMed link      E-mail link

Reference Number: 1386
Ogunwobi OO1, Puszyk W, Dong HJ, Liu C. Epigenetic upregulation of HGF and c-Met drives metastasis in hepatocellular carcinoma. PLoS One. 8, e63765 (2013)
PubMed link      E-mail link

Reference Number: 1387
Tanahashi T1, Osada S, Yamada A, Kato J, Yawata K, Mori R, Imai H, Sasaki Y, Saito S, Tanaka Y, Nonaka K, Yoshida K. Extracellular signal-regulated kinase and Akt activation play a critical role in the process of hepatocyte growth factor-induced epithelial-mesenchymal transition. Int J Oncol. 42, 556-64 (2013)
PubMed link      E-mail link

Reference Number: 1400
Costantini S1, Capone F, Maio P, Guerriero E, Colonna G, Izzo F, Castello G. Cancer biomarker profiling in patients with chronic hepatitis C virus, liver cirrhosis and hepatocellular carcinoma. Oncol Rep. 29, 2163-8 (2013)
PubMed link      E-mail link

Reference Number: 1425
Yang X1, Zhang XF, Lu X, Jia HL, Liang L, Dong QZ, Ye QH, Qin LX. MicroRNA-26a suppresses angiogenesis in human hepatocellular carcinoma by targeting hepatocyte growth factor-cMet pathway. Hepatology. 59, 1874-85 (2014)
PubMed link      E-mail link

Reference Number: 1426
Li X1, Bian Y, Takizawa Y, Hashimoto T, Ikoma T, Tanaka J, Kitamura N, Inagaki Y, Komada M, Tanaka T. ERK-dependent downregulation of Skp2 reduces Myc activity with HGF, leading to inhibition of cell proliferation through a decrease in Id1 expression. Mol Cancer Res. 11, 1437-47 (2013)
PubMed link      E-mail link

Reference Number: 1476
Yu G, Jing Y, Kou X, Ye F, Gao L, Fan Q, Yang Y, Zhao Q, Li R, Wu M, Wei L. Hepatic stellate cells secreted hepatocyte growth factor contributes to the chemoresistance of hepatocellular carcinoma. PLoS One. 8, e73312 (2013)
PubMed link      E-mail link

Reference Number: 1481
Karabulut S, Tas F, Akyüz F, Ormeci AC, Serilmez M, Soydinç HO, Vatansever S, Yasasever V. Clinical significance of serum hepatocyte growth factor (HGF) levels in hepatocellular carcinoma. Tumour Biol. 35, 2327-33 (2014)
PubMed link      E-mail link

Reference Number: 1496
Jia CC, Wang TT, Liu W, Fu BS, Hua X, Wang GY, Li TJ, Li X, Wu XY, Tai Y, Zhou J, Chen GH, Zhang Q. Cancer-associated fibroblasts from hepatocellular carcinoma promote malignant cell proliferation by HGF secretion. PLoS One. 8, e63243 (2013)
PubMed link      E-mail link

Reference Number: 1526
Muñoz Ú, Puche JE, Hannivoort R, Lang UE, Cohen-Naftaly M, Friedman SL. Hepatocyte growth factor enhances alternative splicing of the Kruppel-like factor 6 (KLF6) tumor suppressor to promote growth through SRSF1. Mol Cancer Res. 10, 1216-27 (2012)
PubMed link      E-mail link

Met expression

Reference Number: 72
Kiss, A., Wang, N. J., Xie, J. P. & Thorgeirsson, S. S. Analysis of transforming growth factor (TGF)-alpha/epidermal growth factor receptor, hepatocyte growth Factor/c-met,TGF-beta receptor type II, and p53 expression in human hepatocellular carcinomas. Clin Cancer Res 3, 1059-66 (1997).
PubMed link      E-mail link

Reference Number: 73
Ljubimova, J. Y., Petrovic, L. M., Wilson, S. E., Geller, S. A. & Demetriou, A. A. Expression of HGF, its receptor c-met, c-myc, and albumin in cirrhotic and neoplastic human liver tissue. J Histochem Cytochem 45, 79-87 (1997).
PubMed link      E-mail link

Reference Number: 74
Schoedel, K. E., Tyner, V. Z., Kim, T. H., Michalopoulos, G. K. & Mars, W. M. HGF, MET, and Matrix-Related Proteases in Hepatocellular Carcinoma, Fibrolamellar Variant, Cirrhotic and Normal Liver. Mod Pathol 16, 14-21 (2003).
PubMed link      E-mail link

Reference Number: 75
Selden, C. et al. Expression of hepatocyte growth factor mRNA, and c-met mRNA (hepatocyte growth factor receptor) in human liver tumours. J Hepatol 21, 227-34 (1994).
PubMed link      E-mail link

Reference Number: 76
Ueki, T., Fujimoto, J., Suzuki, T., Yamamoto, H. & Okamoto, E. Expression of hepatocyte growth factor and its receptor, the c-met proto-oncogene, in hepatocellular carcinoma. Hepatology 25, 619-23 (1997).
PubMed link      E-mail link

Reference Number: 403
Zhang SZ, Pan FY, Xu JF, Yuan J, Guo SY, Dai G, Xue B, Shen WG, Wen CJ, Zhao DH, Li CJ. Knockdown of c-Met by adenovirus-delivered small interfering RNA inhibits hepatocellular carcinoma growth in vitro and in vivo. Mol Cancer Ther. 4, 1577-84 (2005)
PubMed link      E-mail link

Reference Number: 449
Ranganathan S, Tan X, Monga SP. beta-Catenin and met deregulation in childhood Hepatoblastomas. Pediatr Dev Pathol.  8, 435-47 (2005)
PubMed link      E-mail link

Reference Number: 450
Osada S, Kanematsu M, Imai H, Goshima S, Sugiyama Y. Evaluation of extracellular signal regulated kinase expression and its relation to treatment of hepatocellular carcinoma. J Am Coll Surg. 201, 405-11 (2005)
PubMed link      E-mail link

Reference Number: 454
Elchuri S, Oberley TD, Qi W, Eisenstein RS, Jackson Roberts L, Van Remmen H, Epstein CJ, Huang TT. CuZnSOD deficiency leads to persistent and widespread oxidative damage and hepatocarcinogenesis later in life. Oncogene. 24, 367-80 (2005)
PubMed link      E-mail link

Reference Number: 468
Yang H, Magilnick N, Noureddin M, Mato JM, Lu SC. Effect of hepatocyte growth factor on methionine adenosyltransferase genes and growth is cell density-dependent in HepG2 cells. J Cell Physiol. 210, 766-73 (2007)
PubMed link      E-mail link

Reference Number: 471
Tward AD, Jones KD, Yant S, Kay MA, Wang R, Bishop JM. Genomic progression in mouse models for liver tumors. Cold Spring Harb Symp Quant Biol. 70, 217-24 (2005)
PubMed link      E-mail link

Reference Number: 476
Kaposi-Novak P, Lee JS, Gomez-Quiroz L, Coulouarn C, Factor VM, Thorgeirsson SS. Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype. J Clin Invest. 116, 1582-95 (2006)
PubMed link      E-mail link

Reference Number: 477
Wu F, Wu L, Zheng S, Ding W, Teng L, Wang Z, Ma Z, Zhao W. The clinical value of hepatocyte growth factor and its receptor--c-met for liver cancer patients with hepatectomy. Dig Liver Dis. 38, 490-7 (2006)
PubMed link      E-mail link

Reference Number: 611
Tward AD, Jones KD, Yant S, Cheung ST, Fan ST, Chen X, Kay MA, Wang R, Bishop JM. Distinct pathways of genomic progression to benign and malignant tumors of the liver. Proc Natl Acad Sci U S A. 104, 14771-6 (2007)
PubMed link      E-mail link

Reference Number: 612
Salvi A, Arici B, Portolani N, Giulini SM, De Petro G, Barlati S. In vitro c-met inhibition by antisense RNA and plasmid-based RNAi down-modulates migration and invasion of hepatocellular carcinoma cells. Int J Oncol. 31, 451-60 (2007)
PubMed link      E-mail link

Reference Number: 632
Takami T, Kaposi-Novak P, Uchida K, Gomez-Quiroz LE, Conner EA, Factor VM, Thorgeirsson SS. Loss of hepatocyte growth factor/c-Met signaling pathway accelerates early stages of N-nitrosodiethylamine induced hepatocarcinogenesis. Cancer Res. 67, 9844-51 (2007)
PubMed link      E-mail link

Reference Number: 633
Towner RA, Smith N, Tesiram YA, Abbott A, Saunders D, Blindauer R, Herlea O, Silasi-Mansat R, Lupu F. In vivo detection of c-MET expression in a rat hepatocarcinogenesis model using molecularly targeted magnetic resonance imaging. Mol Imaging. 6, 18-29 (2007)
PubMed link      E-mail link

Reference Number: 645
Lee KH, Choi EY, Hyun MS, Jang BI, Kim TN, Lee HJ, Eun JY, Kim HG, Yoon SS, Lee DS, Kim JH, Kim JR. Role of hepatocyte growth factor/c-Met signaling in regulating urokinase plasminogen activator on invasiveness in human hepatocellular carcinoma: a potential therapeutic target. Clin Exp Metastasis. 25, 89-96 (2008)
PubMed link      E-mail link

Reference Number: 658
Zeng ZS, Weiser MR, Kuntz E, Chen CT, Khan SA, Forslund A, Nash GM, Gimbel M, Yamaguchi Y, Culliford AT 4th, D'Alessio M, Barany F, Paty PB. c-Met gene amplification is associated with advanced stage colorectal cancer and liver metastases. Cancer Lett. 265, 258-69 (2008)
PubMed link      E-mail link

Reference Number: 681
Chau GY, Lui WY, Chi CW, Chau YP, Li AF, Kao HL, Wu CW. Significance of serum hepatocyte growth factor levels in patients with hepatocellular carcinoma undergoing hepatic resection. Eur J Surg Oncol. 34, 333-8 (2008)
PubMed link      E-mail link

Reference Number: 717
Osada S, Kanematsu M, Imai H, Goshima S. Clinical significance of serum HGF and c-Met expression in tumor tissue for evaluation of properties and treatment of hepatocellular carcinoma. Hepatogastroenterology. 55, 544-9 (2008)
PubMed link      E-mail link

Reference Number: 721
Li N, Fu H, Tie Y, Hu Z, Kong W, Wu Y, Zheng X. miR-34a inhibits migration and invasion by down-regulation of c-Met expression in human hepatocellular carcinoma cells. Cancer Lett. 275, 44-53 Epub 2008 Nov 8. (2009)
PubMed link      E-mail link

Reference Number: 803
Xie B, Xing R, Chen P, Gou Y, Li S, Xiao J, Dong J. Down-regulation of c-Met expression inhibits human HCC cells growth and invasion by RNA interference. J Surg Res. 162, 231-8 (2010)
PubMed link      E-mail link

Reference Number: 900
Singhal G, Rajeswari MR. Interaction of actinomycin D with promoter element of c-met and its inhibitory effect on the expression of c-Met. J Biomol Struct Dyn. 26, 625-36 (2009)
PubMed link      E-mail link

Reference Number: 901
Patil MA, Lee SA, Macias E, Lam ET, Xu C, Jones KD, Ho C, Rodriguez-Puebla M, Chen X. Role of cyclin D1 as a mediator of c-Met- and beta-catenin-induced hepatocarcinogenesis. Cancer Res. 69, 253-61 (2009)
PubMed link      E-mail link

Reference Number: 903
Kaufmann R, Oettel C, Horn A, Halbhuber KJ, Eitner A, Krieg R, Katenkamp K, Henklein P, Westermann M, Böhmer FD, Ramachandran R, Saifeddine M, Hollenberg MD, Settmacher U. Met receptor tyrosine kinase transactivation is involved in proteinase-activated receptor-2-mediated hepatocellular carcinoma cell invasion. Carcinogenesis. 30, 1487-96 (2009)
PubMed link      E-mail link

Reference Number: 909
Marx-Stoelting P, Borowiak M, Knorpp T, Birchmeier C, Buchmann A, Schwarz M. Hepatocarcinogenesis in mice with a conditional knockout of the hepatocyte growth factor receptor c-Met. Int J Cancer. 124, 1767-72 (2009)
PubMed link      E-mail link

Reference Number: 1025
Purcell R, Childs M, Maibach R, Miles C, Turner C, Zimmermann A, Sullivan M. HGF/c-Met related activation of ß-catenin in hepatoblastoma. J Exp Clin Cancer Res. 30:96 (2011)
PubMed link      E-mail link

Reference Number: 1027
Schelter F, Grandl M, Seubert B, Schaten S, Hauser S, Gerg M, Boccaccio C, Comoglio P, Krüger A. Tumor cell-derived Timp-1 is necessary for maintaining metastasis-promoting Met-signaling via inhibition of Adam-10. Clin Exp Metastasis. 28, 793-802 (2011)
PubMed link      E-mail link

Reference Number: 1033
Carr BI, Wang Z, Wang M, Cavallini A, D'Alessandro R, Refolo MG. c-Met-Akt pathway-mediated enhancement of inhibitory c-Raf phosphorylation is involved in vitamin K1 and sorafenib synergy on HCC growth inhibition. Cancer Biol Ther. 12, 531-8 (2011)
PubMed link      E-mail link

Reference Number: 1035
Qiu J, Huang P, Liu Q, Hong J, Li B, Lu C, Wang L, Wang J, Yuan Y. Identification of MACC1 as a novel prognostic marker in hepatocellular carcinoma. J Transl Med. 9, 166 (2011)
PubMed link      E-mail link

Reference Number: 1106
Tan S, Li R, Ding K, Lobie PE, Zhu T. miR-198 inhibits migration and invasion of hepatocellular carcinoma cells by targeting the HGF/c-MET pathway. FEBS Lett. 585, 2229-34 (2011)
PubMed link      E-mail link

Reference Number: 1148
Dai R, Li J, Fu J, Chen Y, Yu L, Zhao X, Qian Y, Zhang H, Chen H, Ren Y, Su B, Luo T, Zhu J, Wang H. Disturbance of Ca2 homeostasis converts pro-Met into non-canonical tyrosine kinase p190MetNC in response to endoplasmic reticulum stress in MHCC97 cells. J Biol Chem. 287, 14586-97 (2012)
PubMed link      E-mail link

Reference Number: 1227
Qu JH, Chang XJ, Lu YY, Bai WL, Chen Y, Zhou L, Zeng Z, Wang CP, An LJ, Hao LY, Xu GL, Gao XD, Lou M, Lv JY, Yang YP. Overexpression of metastasis-associated in colon cancer 1 predicts a poor outcome of hepatitis B virus-related hepatocellular carcinoma. World J Gastroenterol. 18, 2995-3003 (2012)
PubMed link      E-mail link

Reference Number: 1258
Nguyen TH, Loux N, Dagher I, Vons C, Carey K, Briand P, Hadchouel M, Franco D, Jouanneau J, Schwall R, Weber A. Improved gene transfer selectivity to hepatocarcinoma cells by retrovirus vector displaying single-chain variable fragment antibody against c-Met. Cancer Gene Ther. 10, 840-9 (2003)
PubMed link      E-mail link

Reference Number: 1273
Bozkaya G, Korhan P, Cokakli M, Erdal E, Sagol O, Karademir S, Korch C, Atabey N. Cooperative interaction of MUC1 with the HGF/c-Met pathway during hepatocarcinogenesis. Mol Cancer. 11, 64 (2012)
PubMed link      E-mail link

Reference Number: 1283
Buurman R, Gürlevik E, Schäffer V, Eilers M, Sandbothe M, Kreipe H, Wilkens L, Schlegelberger B, Kühnel F, Skawran B. Histone deacetylases activate hepatocyte growth factor signaling by repressing microRNA-449 in hepatocellular carcinoma cells. Gastroenterology. 143, 811-20 (2012)
PubMed link      E-mail link

Reference Number: 1296
Isella C, Mellano A, Galimi F, Petti C, Capussotti L, De Simone M, Bertotti A, Medico E, Muratore A. MACC1 mRNA levels predict cancer recurrence after resection of colorectal cancer liver metastases. Ann Surg. 257, 1089-95 (2013)
PubMed link      E-mail link

Reference Number: 1302
Trojan J, Zeuzem S. Tivantinib in hepatocellular carcinoma. Expert Opin Investig Drugs. 22, 141-7 (2013)
PubMed link      E-mail link

Reference Number: 1335
Gao J, Feng X, Inagaki Y, Song P, Kokudo N, Hasegawa K, Sugawara Y, Tang W. Des-?-carboxy prothrombin and c-Met were concurrently and extensively expressed in hepatocellular carcinoma and associated with tumor recurrence. Biosci Trends. 6, 153-9 (2012)
PubMed link      E-mail link

Reference Number: 1368
Ang CS, Sun MY, Huitzil-Melendez DF, Chou JF, Capanu M, Jarnagin W, Fong Y, Dematteo RP, D'Angelica M, Allen P, Chen CT, O'Reilly EM, Weiser MR, Abou-Alfa GK. c-MET and HGF mRNA expression in hepatocellular carcinoma: correlation with clinicopathological features and survival. Anticancer Res. 33, 3241-5 (2013)
PubMed link      E-mail link

Reference Number: 1381
Kondo S1, Ojima H, Tsuda H, Hashimoto J, Morizane C, Ikeda M, Ueno H, Tamura K, Shimada K, Kanai Y, Okusaka T. Clinical impact of c-Met expression and its gene amplification in hepatocellular carcinoma. Int J Clin Oncol. 18, 207-13 (2013)
PubMed link      E-mail link

Reference Number: 1386
Ogunwobi OO1, Puszyk W, Dong HJ, Liu C. Epigenetic upregulation of HGF and c-Met drives metastasis in hepatocellular carcinoma. PLoS One. 8, e63765 (2013)
PubMed link      E-mail link

Reference Number: 1394
Lee SJ1, Lee J, Sohn I, Mao M, Kai W, Park CK, Lim HY. A survey of c-MET expression and amplification in 287 patients with hepatocellular carcinoma. Anticancer Res. 33, 5179-86 (2013)
PubMed link      E-mail link

Reference Number: 1399
Hu CT1, Cheng CC, Pan SM, Wu JR, Wu WS. PKC mediates fluctuant ERK-paxillin signaling for hepatocyte growth factor-induced migration of hepatoma cell HepG2. Cell Signal. 25, 1457-67 (2013)
PubMed link      E-mail link

Reference Number: 1425
Yang X1, Zhang XF, Lu X, Jia HL, Liang L, Dong QZ, Ye QH, Qin LX. MicroRNA-26a suppresses angiogenesis in human hepatocellular carcinoma by targeting hepatocyte growth factor-cMet pathway. Hepatology. 59, 1874-85 (2014)
PubMed link      E-mail link

Reference Number: 1457
Harun N, Costa P, Christophi C. Tumour growth stimulation following partial hepatectomy in mice is associated with increased upregulation of c-Met. Clin Exp Metastasis. 31, 1-14 (2014)
PubMed link      E-mail link

Reference Number: 1477
Chen CK, Yang CY, Hua KT, Ho MC, Johansson G, Jeng YM, Chen CN, Chen MW, Lee WJ, Su JL, Lai TC, Chou CC, Ho BC, Chang CF, Lee PH, Chang KJ, Hsiao M, Lin MT, Kuo ML. Leukocyte cell-derived chemotaxin 2 antagonizes MET receptor activation to suppress hepatocellular carcinoma vascular invasion by protein tyrosine phosphatase 1B recruitment. Hepatology. 59, 974-85 (2014)
PubMed link      E-mail link

Reference Number: 1492
Chu JS, Ge FJ, Zhang B, Wang Y, Silvestris N, Liu LJ, Zhao CH, Lin L, Brunetti AE, Fu YL, Wang J, Paradiso A, Xu JM. Expression and prognostic value of VEGFR-2, PDGFR-ß, and c-Met in advanced hepatocellular carcinoma. J Exp Clin Cancer Res. 32, 16 (2013)
PubMed link      E-mail link

Reference Number: 1548
Korhan P, Erdal E, Atabey N. MiR-181a-5p is downregulated in hepatocellular carcinoma and suppresses motility, invasion and branching-morphogenesis by directly targeting c-Met. Biochem Biophys Res Commun. 450, 1304-12 (2014)
PubMed link      E-mail link

Reference Number: 1552
Kang GH, Lee BS, Lee ES, Kim SH, Lee HY, Kang DY. Prognostic significance of p53, mTOR, c-Met, IGF-1R, and HSP70 overexpression after the resection of hepatocellular carcinoma. Gut Liver. 8, 79-87 (2014)
PubMed link      E-mail link

Reference Number: 1651
Rimassa L, Santoro A, Daniele B, Germano D, Gasbarrini A, Salvagni S, Masi G, Abbadessa G, Lamar M, Goldberg T, Porta C. Tivantinib, a new option for second-line treatment of advanced hepatocellular carcinoma? The experience of Italian centers. Tumori. 101, 139-43 (2015)
PubMed link      E-mail link

Reference Number: 1662
Bogorad RL, Yin H, Zeigerer A, Nonaka H, Ruda VM, Zerial M, Anderson DG, Koteliansky V. Nanoparticle-formulated siRNA targeting integrins inhibits hepatocellular carcinoma progression in mice. Nat Commun. 5, 3869 (2014)
PubMed link      E-mail link

Reference Number: 1686
Mußbach F, Henklein P, Westermann M, Settmacher U, Böhmer FD, Kaufmann R. Proteinase-activated receptor 1- and 4-promoted migration of Hep3B hepatocellular carcinoma cells depends on ROS formation and RTK transactivation. J Cancer Res Clin Oncol. 141, 813-25 (2015)
PubMed link      E-mail link

Reference Number: 1696
Korhan P, Erdal E, Kandemis E, Cokakli M, Nart D, Yilmaz F, Can A, Atabey N. Reciprocal activating crosstalk between c-Met and caveolin 1 promotes invasive phenotype in hepatocellular carcinoma. PLoS One., 9(8):e105278 (2014)
PubMed link      E-mail link

Reference Number: 1788
Koh YW, Park YS, Kang HJ, Shim JH, Yu E. MET is a predictive factor for late recurrence but not for overall survival of early stage hepatocellular carcinoma. Tumour Biol. 36, 4993-5000 (2015)
PubMed link      E-mail link

Reference Number: 1808
Gui Y, Yeganeh M, Donates YC, Tobelaim WS, Chababi W, Mayhue M, Yoshimura A, Ramanathan S, Saucier C, Ilangumaran S Regulation of MET receptor tyrosine kinase signaling by suppressor of cytokine signaling 1 in hepatocellular carcinoma. Oncogene. 34, 5718-28 (2015)
PubMed link      E-mail link

Reference Number: 1825
Yao Y, Dou C, Lu Z, Zheng X, Liu Q. MACC1 suppresses cell apoptosis in hepatocellular carcinoma by targeting the HGF/c-MET/AKT pathway. Cell Physiol Biochem. 35, 983-96 (2015)
PubMed link      E-mail link

Reference Number: 1827
Wu JR, Hu CT, You RI, Ma PL, Pan SM, Lee MC, Wu WS. Preclinical trials for prevention of tumor progression of hepatocellular carcinoma by LZ-8 targeting c-Met dependent and independent pathways. PLoS One. 10, e0114495 (2015)
PubMed link      E-mail link

Reference Number: 1836
Zhao L, Wu Y, Xie XD, Chu YF, Li JQ, Zheng L. c-Met identifies a population of matrix metalloproteinase 9-producing monocytes in peritumoural stroma of hepatocellular carcinoma. J Pathol. 237, 319-29 (2015)
PubMed link      E-mail link

Reference Number: 1879
Ohta K, Hoshino H, Wang J, Ono S, Iida Y, Hata K, Huang SK, Colquhoun S, Hoon DS. MicroRNA-93 activates c-Met/PI3K/Akt pathway activity in hepatocellular carcinoma by directly inhibiting PTEN and CDKN1A. Oncotarget. 6, 3211-24 (2015)
PubMed link      E-mail link

Reference Number: 1900
Gui Y, Yeganeh M, Cepero-Donates Y, Ramanathan S, Saucier C, Ilangumaran S, Regulation of MET receptor signaling by SOCS1 and its implications for hepatocellular carcinoma. Curr Pharm Des. 20, 2922-33 (2014)
PubMed link      E-mail link

Poor Prognosis

Reference Number: 76
Ueki, T., Fujimoto, J., Suzuki, T., Yamamoto, H. & Okamoto, E. Expression of hepatocyte growth factor and its receptor, the c-met proto-oncogene, in hepatocellular carcinoma. Hepatology 25, 619-23 (1997).
PubMed link      E-mail link

Reference Number: 253
Daveau M, Scotte M, Francois A, Coulouarn C, Ros G, Tallet Y, Hiron M, Hellot MF, Salier JP. Hepatocyte growth factor, transforming growth factor alpha, and their receptors as combined markers of prognosis in hepatocellular carcinoma. Mol Carcinog 36:13-41 (2003).
PubMed link      E-mail link

Reference Number: 476
Kaposi-Novak P, Lee JS, Gomez-Quiroz L, Coulouarn C, Factor VM, Thorgeirsson SS. Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype. J Clin Invest. 116, 1582-95 (2006)
PubMed link      E-mail link

Reference Number: 504
Gotohda N, Iwagaki H, Ozaki M, Konishi M, Nakagohri T, Takahashi S, Yagi T, Kinoshita T, Tanaka N. The role of a protease inhibitor against hepatectomy. Hepatogastroenterology. 53, 115-9 (2006)
PubMed link      E-mail link

Reference Number: 723
Ke AW, Shi GM, Zhou J, Wu FZ, Ding ZB, Hu MY, Xu Y, Song ZJ, Wang ZJ, Wu JC, Bai DS, Li JC, Liu KD, Fan J. Role of overexpression of CD151 and/or c-Met in predicting prognosis of hepatocellular carcinoma. Hepatology. 49, 491-503 (2009)
PubMed link      E-mail link

Reference Number: 1273
Bozkaya G, Korhan P, Cokakli M, Erdal E, Sagol O, Karademir S, Korch C, Atabey N. Cooperative interaction of MUC1 with the HGF/c-Met pathway during hepatocarcinogenesis. Mol Cancer. 11, 64 (2012)
PubMed link      E-mail link

Reference Number: 1335
Gao J, Feng X, Inagaki Y, Song P, Kokudo N, Hasegawa K, Sugawara Y, Tang W. Des-?-carboxy prothrombin and c-Met were concurrently and extensively expressed in hepatocellular carcinoma and associated with tumor recurrence. Biosci Trends. 6, 153-9 (2012)
PubMed link      E-mail link

Reference Number: 1899
Zhu C, Utsunomiya T, Ikemoto T, Yamada S, Morine Y, Imura S, Arakawa Y, Takasu C, Ishikawa D, Imoto I, Shimada M. Hypomethylation of long interspersed nuclear element-1 (LINE-1) is associated with poor prognosis via activation of c-MET in hepatocellular carcinoma. Ann Surg Oncol. 21 Suppl 4, S729-35 (2014)
PubMed link      E-mail link

Mutation of Met

Reference Number: 77
Park, W. S. et al. Somatic mutations in the kinase domain of the Met/hepatocyte growth factor receptor gene in childhood hepatocellular carcinomas. Cancer Res 59, 307-10 (1999).
PubMed link      E-mail link

In vitro studies

Reference Number: 78
Xie, Q., Liu, K. D., Hu, M. Y. & Zhou, K. SF/HGF-c-Met autocrine and paracrine promote metastasis of hepatocellular carcinoma. World J Gastroenterol 7, 816-20 (2001).
PubMed link      E-mail link

Reference Number: 254
Ozaki I, Mizuta T, Zhao G, Zhang H, Yoshimura T, Kawazoe S, Eguchi Y, Yasutake T, Hisatomi A, Sakai T, Yamamoto K. Induction of multiple matrix metalloproteinase genes in human hepatocellular carcinoma by hepatocyte growth factor via a transcription factor Ets-1. Hepatol Res 27:289-301 (2003).
PubMed link      E-mail link

Reference Number: 255
Jiang Y, Xu W, Lu J, He F, Yang X. Invasiveness of hepatocellular carcinoma cell lines: contribution of hepatocyte growth factor, c-met, and transcription factor Ets-1. Biochem Biophys Res Commun 286:1123-30 (2001).
PubMed link      E-mail link

Reference Number: 402
Imai Y, Kubota Y, Yamamoto S, Tsuji K, Shimatani M, Shibatani N, Takamido S, Matsushita M, Okazaki K. Neutrophils enhance invasion activity of human cholangiocellular carcinoma and hepatocellular carcinoma cells: an in vitro study. J Gastroenterol Hepatol. 20, 287-93 (2005)
PubMed link      E-mail link

Reference Number: 403
Zhang SZ, Pan FY, Xu JF, Yuan J, Guo SY, Dai G, Xue B, Shen WG, Wen CJ, Zhao DH, Li CJ. Knockdown of c-Met by adenovirus-delivered small interfering RNA inhibits hepatocellular carcinoma growth in vitro and in vivo. Mol Cancer Ther. 4, 1577-84 (2005)
PubMed link      E-mail link

Reference Number: 451
Han J, Tsukada Y, Hara E, Kitamura N, Tanaka T. Hepatocyte growth factor induces redistribution of p21(CIP1) and p27(KIP1) through ERK-dependent p16(INK4a) up-regulation, leading to cell cycle arrest at G1 in HepG2 hepatoma cells. J Biol Chem. 280, 31548-56 (2005)
PubMed link      E-mail link

Reference Number: 453
Wang Z, Wang M, Carr BI. Hepatocyte growth factor enhances protein phosphatase Cdc25A inhibitor compound 5-induced hepatoma cell growth inhibition via Akt-mediated MAPK pathway. J Cell Physiol. 203, 510-9 (2005)
PubMed link      E-mail link

Reference Number: 468
Yang H, Magilnick N, Noureddin M, Mato JM, Lu SC. Effect of hepatocyte growth factor on methionine adenosyltransferase genes and growth is cell density-dependent in HepG2 cells. J Cell Physiol. 210, 766-73 (2007)
PubMed link      E-mail link

Reference Number: 478
Lasagna N, Fantappie O, Solazzo M, Morbidelli L, Marchetti S, Cipriani G, Ziche M, Mazzanti R. Hepatocyte growth factor and inducible nitric oxide synthase are involved in multidrug resistance-induced angiogenesis in hepatocellular carcinoma cell lines. Cancer Res. 66, 2673-82 (2006)
PubMed link      E-mail link

Reference Number: 496
Kondo A, Hirayama N, Sugito Y, Shono M, Tanaka T, Kitamura N. Coupling of Grb2 to Gab1 mediates hepatocyte growth factor-induced high intensity ERK signal required for inhibition of HepG2 hepatoma cell proliferation. J Biol Chem. 283, 1428-36 (2008)
PubMed link      E-mail link

Reference Number: 616
Matsumoto Y, Motoki T, Kubota S, Takigawa M, Tsubouchi H, Gohda E. Inhibition of tumor-stromal interaction through HGF/Met signaling by valproic acid. Biochem Biophys Res Commun. 366, 110-6 (2007)
PubMed link      E-mail link

Reference Number: 663
Takahara T, Xue F, Mazzone M, Yata Y, Nonome K, Kanayama M, Kawai K, Pisacane AM, Takahara S, Li XK, Comoglio PM, Sugiyama T, Michieli P. Metron factor-1 prevents liver injury without promoting tumor growth and metastasis. Hepatology. 47, 2010-25 (2008)
PubMed link      E-mail link

Reference Number: 698
Lee KH, Choi EY, Hyun MS, Eun JR, Jang BI, Kim TN, Lee HJ, Lee DS, Yun SS, Kim HJ, Kim JH, Kim JR. Cellular mechanisms of hepatocyte growth factor-mediated urokinase plasminogen activator secretion by MAPK signaling in hepatocellular carcinoma. Tumori. 94, 523-30 (2008)
PubMed link      E-mail link

Reference Number: 803
Xie B, Xing R, Chen P, Gou Y, Li S, Xiao J, Dong J. Down-regulation of c-Met expression inhibits human HCC cells growth and invasion by RNA interference. J Surg Res. 162, 231-8 (2010)
PubMed link      E-mail link

Reference Number: 852
Piscaglia AC, Shupe TD, Pani G, Tesori V, Gasbarrini A, Petersen BE. Establishment of cancer cell lines from rat hepatocholangiocarcinoma and assessment of the role of granulocyte-colony stimulating factor and hepatocyte growth factor in their growth, motility and survival. J Hepatol. 51, 77-92 (2009)
PubMed link      E-mail link

Reference Number: 903
Kaufmann R, Oettel C, Horn A, Halbhuber KJ, Eitner A, Krieg R, Katenkamp K, Henklein P, Westermann M, Böhmer FD, Ramachandran R, Saifeddine M, Hollenberg MD, Settmacher U. Met receptor tyrosine kinase transactivation is involved in proteinase-activated receptor-2-mediated hepatocellular carcinoma cell invasion. Carcinogenesis. 30, 1487-96 (2009)
PubMed link      E-mail link

Reference Number: 906
Grotegut S, Kappler R, Tarimoradi S, Lehembre F, Christofori G, Von Schweinitz D. Hepatocyte growth factor protects hepatoblastoma cells from chemotherapy-induced apoptosis by AKT activation. Int J Oncol. 36, 1261-7 (2010)
PubMed link      E-mail link

Reference Number: 938
Schrötzlmair F, Kopitz C, Halbgewachs B, Lu F, Algül H, Brünner N, Gänsbacher B, Krüger A. Tissue inhibitor of metalloproteinases-1-induced scattered liver metastasis is mediated by host-derived urokinase-type plasminogen activator. J Cell Mol Med. 14, 2760-70 (2010)
PubMed link      E-mail link

Reference Number: 1033
Carr BI, Wang Z, Wang M, Cavallini A, D'Alessandro R, Refolo MG. c-Met-Akt pathway-mediated enhancement of inhibitory c-Raf phosphorylation is involved in vitamin K1 and sorafenib synergy on HCC growth inhibition. Cancer Biol Ther. 12, 531-8 (2011)
PubMed link      E-mail link

Reference Number: 1043
Ogunwobi OO, Liu C. Hepatocyte growth factor upregulation promotes carcinogenesis and epithelial-mesenchymal transition in hepatocellular carcinoma via Akt and COX-2 pathways. Clin Exp Metastasis. 28, 721-31 (2011)
PubMed link      E-mail link

Reference Number: 1312
Liu Z, Feng Z, Zhu X, Xu W, Zhu J, Zhang X, Fan Z, Ji G. Construction, expression, and characterization of an anti-tumor immunotoxin containing the human anti-c-Met single-chain antibody and PE38KDEL. Immunol Lett. 149, 30-40 (2013)
PubMed link      E-mail link

Reference Number: 1367
Dang Y, Luo D, Rong M, Chen G. Underexpression of miR-34a in hepatocellular carcinoma and its contribution towards enhancement of proliferating inhibitory effects of agents targeting c-MET. PLoS One. 8, e61054 (2013)
PubMed link      E-mail link

Reference Number: 1370
Takeda S, Liu H, Sasagawa S, Dong Y, Trainor PA, Cheng EH, Hsieh JJ. HGF-MET signals via the MLL-ETS2 complex in hepatocellular carcinoma. J Clin Invest. 123, 3154-65 (2013)
PubMed link      E-mail link

Reference Number: 1377
Li Y, Huang X, Zhang Q, Ma K. Phosphorylation of cMet tyrosine residues in murine ascitic hepatic cancer cell lines with different lymph node metastatic potentials. Mol Med Rep. 8, 655-61 (2013)
PubMed link      E-mail link

Reference Number: 1482
Dai W, Wang C, Wang F, Wang Y, Shen M, Chen K, Cheng P, Zhang Y, Yang J, Zhu R, Zhang H, Li J, Zheng Y, Lu J, Zhou Y, Xu L, Guo C. Anti-miR-197 inhibits migration in HCC cells by targeting KAI 1/CD82. Biochem Biophys Res Commun. 446, 541-8 (2014)
PubMed link      E-mail link

Reference Number: 1493
Shi MD, Liao YC, Shih YW, Tsai LY. Nobiletin attenuates metastasis via both ERK and PI3K/Akt pathways in HGF-treated liver cancer HepG2 cells. Phytomedicine. 20, 743-52 (2013)
PubMed link      E-mail link

Reference Number: 1499
Wu YM, Liu CH, Huang MJ, Lai HS, Lee PH, Hu RH, Huang MC. C1GALT1 enhances proliferation of hepatocellular carcinoma cells via modulating MET glycosylation and dimerization. Cancer Res. 73, 5580-90 (2013)
PubMed link      E-mail link

Animal models

Reference Number: 22
Jakubczak, J. L., LaRochelle, W. J. & Merlino, G. NK1, a natural splice variant of hepatocyte growth factor/scatter factor, is a partial agonist in vivo. Mol Cell Biol 18, 1275-83. (1998).
PubMed link      E-mail link

Reference Number: 79
Amicone, L. et al. Synergy between truncated c-Met (cyto-Met) and c-Myc in liver oncogenesis: importance of TGF-beta signalling in the control of liver homeostasis and transformation. Oncogene 21, 1335-45 (2002).
PubMed link      E-mail link

Reference Number: 80
Bell, A., Chen, Q., DeFrances, M. C., Michalopoulos, G. K. & Zarnegar, R. The five amino acid-deleted isoform of hepatocyte growth factor promotes carcinogenesis in transgenic mice. Oncogene 18, 887-95 (1999).
PubMed link      E-mail link

Reference Number: 81
Horiguchi, N. et al. Hepatocyte growth factor promotes hepatocarcinogenesis through c-Met autocrine activation and enhanced angiogenesis in transgenic mice treated with diethylnitrosamine. Oncogene 21, 1791-9 (2002).
PubMed link      E-mail link

Reference Number: 82
Nakayama, N. et al. Hepatocyte growth factor and c-met expression in Long-Evans Cinnamon rats with spontaneous hepatitis and hepatoma. Hepatology 24, 596-602. (1996).
PubMed link      E-mail link

Reference Number: 83
Price, J. A. et al. . Hepatology 36, 1089-97. (2002).
PubMed link      E-mail link

Reference Number: 84
Sakata, H. et al. Hepatocyte growth factor/scatter factor overexpression induces growth, abnormal development, and tumor formation in transgenic mouse livers. Cell Growth Differ 7, 1513-23 (1996).
PubMed link      E-mail link

Reference Number: 85
Santoni-Rugiu, E. et al. Inhibition of neoplastic development in the liver by hepatocyte growth factor in a transgenic mouse model. Proc Natl Acad Sci U S A 93, 9577-82. (1996).
PubMed link      E-mail link

Reference Number: 86
Shiota, G., Kawasaki, H., Nakamura, T. & Schmidt, E. V. Inhibitory effect of hepatocyte growth factor on metastasis of hepatocellular carcinoma in transgenic mice. Res Commun Mol Pathol Pharmacol 91, 33-9 (1996).
PubMed link      E-mail link

Reference Number: 251
Scarpino S, D'Alena FC, Di Napoli A, Ballarini F, Prat M, Ruco LP. Papillary carcinoma of the thyroid: evidence for a role for hepatocyte growth factor (HGF) in promoting tumour angiogenesis. J Pathol 199:243-50 (2003).
PubMed link      E-mail link

Reference Number: 344
Boccaccio C, Sabatino G, Medico E, Girolami F, Follenzi A, Reato G, Sottile A, Naldini L, Comoglio PM. The MET oncogene drives a genetic programme linking cancer to haemostasis. Nature  434, 396-400 (2005)
PubMed link      E-mail link

Reference Number: 403
Zhang SZ, Pan FY, Xu JF, Yuan J, Guo SY, Dai G, Xue B, Shen WG, Wen CJ, Zhao DH, Li CJ. Knockdown of c-Met by adenovirus-delivered small interfering RNA inhibits hepatocellular carcinoma growth in vitro and in vivo. Mol Cancer Ther. 4, 1577-84 (2005)
PubMed link      E-mail link

Reference Number: 469
Jo J, Yamamoto M, Matsumoto K, Nakamura T, Tabata Y. Liver targeting of plasmid DNA with a cationized pullulan for tumor suppression. J Nanosci Nanotechnol. 6, 2853-9 (2006)
PubMed link      E-mail link

Reference Number: 471
Tward AD, Jones KD, Yant S, Kay MA, Wang R, Bishop JM. Genomic progression in mouse models for liver tumors. Cold Spring Harb Symp Quant Biol. 70, 217-24 (2005)
PubMed link      E-mail link

Reference Number: 472
Son G, Hirano T, Seki E, Iimuro Y, Nukiwa T, Matsumoto K, Nakamura T, Fujimoto J. Blockage of HGF/c-Met system by gene therapy (adenovirus-mediated NK4 gene) suppresses hepatocellular carcinoma in mice. J Hepatol. 45, 688-95 (2006)
PubMed link      E-mail link

Reference Number: 474
Nakanishi C, Moriuchi A, Ido A, Numata M, Kim ID, Kusumoto K, Hasuike S, Abe H, Nagata K, Akiyama Y, Uto H, Kataoka H, Tsubouchi H. Effect of hepatocyte growth factor on endogenous hepatocarcinogenesis in rats fed a choline-deficient L-amino acid-defined diet. Oncol Rep. 16 25-31 (2006)
PubMed link      E-mail link

Reference Number: 540
Yoshida Y, Hirano T, Son G, Iimuro Y, Imado T, Iwasaki T, Fujimoto J. Allogeneic bone marrow transplantation for hepatocellular carcinoma: hepatocyte growth factor suppresses graft-vs.-host disease. Am J Physiol Gastrointest Liver Physiol. 293, G1114-23 (2007)
PubMed link      E-mail link

Reference Number: 558
Meredith K, Haemmerich D, Qi C, Mahvi D. Hepatic resection but not radiofrequency ablation results in tumor growth and increased growth factor expression. Ann Surg. 245, 771-6 (2007)
PubMed link      E-mail link

Reference Number: 573
Isbert C, Ritz JP, Roggan A, Schuppan D, Ajubi N, Buhr HJ, Hohenberger W, Germer CT. Laser-induced thermotherapy (LITT) elevates mRNA expression of connective tissue growth factor (CTGF) associated with reduced tumor growth of liver metastases compared to hepatic resection. Lasers Surg Med. 39, 42-50 (2007)
PubMed link      E-mail link

Reference Number: 611
Tward AD, Jones KD, Yant S, Cheung ST, Fan ST, Chen X, Kay MA, Wang R, Bishop JM. Distinct pathways of genomic progression to benign and malignant tumors of the liver. Proc Natl Acad Sci U S A. 104, 14771-6 (2007)
PubMed link      E-mail link

Reference Number: 632
Takami T, Kaposi-Novak P, Uchida K, Gomez-Quiroz LE, Conner EA, Factor VM, Thorgeirsson SS. Loss of hepatocyte growth factor/c-Met signaling pathway accelerates early stages of N-nitrosodiethylamine induced hepatocarcinogenesis. Cancer Res. 67, 9844-51 (2007)
PubMed link      E-mail link

Reference Number: 633
Towner RA, Smith N, Tesiram YA, Abbott A, Saunders D, Blindauer R, Herlea O, Silasi-Mansat R, Lupu F. In vivo detection of c-MET expression in a rat hepatocarcinogenesis model using molecularly targeted magnetic resonance imaging. Mol Imaging. 6, 18-29 (2007)
PubMed link      E-mail link

Reference Number: 644
Takashima K, Ito Y, Gonzalez FJ, Nakajima T. Different mechanisms of DEHP-induced hepatocellular adenoma tumorigenesis in wild-type and Ppar alpha-null mice. J Occup Health. 50, 169-80 (2008)
PubMed link      E-mail link

Reference Number: 663
Takahara T, Xue F, Mazzone M, Yata Y, Nonome K, Kanayama M, Kawai K, Pisacane AM, Takahara S, Li XK, Comoglio PM, Sugiyama T, Michieli P. Metron factor-1 prevents liver injury without promoting tumor growth and metastasis. Hepatology. 47, 2010-25 (2008)
PubMed link      E-mail link

Reference Number: 684
Huh CG, Factor VM, Sánchez A, Uchida K, Conner EA, Thorgeirsson SS. Hepatocyte growth factor/c-met signaling pathway is required for efficient liver regeneration and repair. Proc Natl Acad Sci U S A. 101, 4477-82 (2004)
PubMed link      E-mail link

Reference Number: 852
Piscaglia AC, Shupe TD, Pani G, Tesori V, Gasbarrini A, Petersen BE. Establishment of cancer cell lines from rat hepatocholangiocarcinoma and assessment of the role of granulocyte-colony stimulating factor and hepatocyte growth factor in their growth, motility and survival. J Hepatol. 51, 77-92 (2009)
PubMed link      E-mail link

Reference Number: 901
Patil MA, Lee SA, Macias E, Lam ET, Xu C, Jones KD, Ho C, Rodriguez-Puebla M, Chen X. Role of cyclin D1 as a mediator of c-Met- and beta-catenin-induced hepatocarcinogenesis. Cancer Res. 69, 253-61 (2009)
PubMed link      E-mail link

Reference Number: 909
Marx-Stoelting P, Borowiak M, Knorpp T, Birchmeier C, Buchmann A, Schwarz M. Hepatocarcinogenesis in mice with a conditional knockout of the hepatocyte growth factor receptor c-Met. Int J Cancer. 124, 1767-72 (2009)
PubMed link      E-mail link

Reference Number: 946
Kubo E, Yoshikawa N, Kunitomo M, Kagota S, Shinozuka K, Nakamura K. Inhibitory effect of Cordyceps sinensis on experimental hepatic metastasis of melanoma by suppressing tumor cell invasion. Anticancer Res. 30, 3429-33 (2010)
PubMed link      E-mail link

Reference Number: 1034
Ivanovska I, Zhang C, Liu AM, Wong KF, Lee NP, Lewis P, Philippar U, Bansal D, Buser C, Scott M, Mao M, Poon RT, Fan ST, Cleary MA, Luk JM, Dai H. Gene signatures derived from a c-MET-driven liver cancer mouse model predict survival of patients with hepatocellular carcinoma. PLoS One. 6, e24582 (2011)
PubMed link      E-mail link

Reference Number: 1386
Ogunwobi OO1, Puszyk W, Dong HJ, Liu C. Epigenetic upregulation of HGF and c-Met drives metastasis in hepatocellular carcinoma. PLoS One. 8, e63765 (2013)
PubMed link      E-mail link

Reference Number: 1435
Shang N, Arteaga M, Zaidi A, Stauffer J, Cotler SJ, Zeleznik-Le NJ, Zhang J, Qiu W. FAK is required for c-Met/ß-catenin-driven hepatocarcinogenesis. Hepatology. 61, 214-26 (2015)
PubMed link      E-mail link

Reference Number: 1457
Harun N, Costa P, Christophi C. Tumour growth stimulation following partial hepatectomy in mice is associated with increased upregulation of c-Met. Clin Exp Metastasis. 31, 1-14 (2014)
PubMed link      E-mail link

Reference Number: 1685
Peterson EA, Teffera Y, Albrecht BK, Bauer D, Bellon SF, Boezio A, Boezio C, Broome MA, Choquette D, Copeland KW, Dussault I, Lewis R, Lin MH, Lohman J, Liu J, Potashman M, Rex K, Shimanovich R, Whittington DA, Vaida KR, Harmange JC. Discovery of potent and selective 8-fluorotriazolopyridine c-Met inhibitors. J Med Chem. 58, 2417-30 (2015)
PubMed link      E-mail link

Therapeutic Development

Reference Number: 292
Wang SY, Chen B, Zhan YQ, Xu WX, Li CY, Yang RF, Zheng H, Yue PB, Larsen SH, Sun HB, Yang X. SU5416 is a potent inhibitor of hepatocyte growth factor receptor (c-Met) and blocks HGF-induced invasiveness of human HepG2 hepatoma cells. J Hepatol 41, 267-73 (2004)
PubMed link      E-mail link

Reference Number: 300
Wen J, Matsumoto K, Taniura N, Tomioka D, Nakamura T. Hepatic gene expression of NK4, an HGF-antagonist/angiogenesis inhibitor, suppresses liver metastasis and invasive growth of colon cancer in mice. Cancer Gene Ther 11, 419-30 (2004)
PubMed link      E-mail link

Reference Number: 328
Yuge K, Takahashi T, Nagano S, Terazaki Y, Murofushi Y, Ushikoshi H, Kawai T, Khai NC, Nakamura T, Fujiwara H, Kosai K. Adenoviral gene transduction of hepatocyte growth factor elicits inhibitory effects for hepatoma. Int J Oncol. 27, 77-85 (2005)
PubMed link      E-mail link

Reference Number: 472
Son G, Hirano T, Seki E, Iimuro Y, Nukiwa T, Matsumoto K, Nakamura T, Fujimoto J. Blockage of HGF/c-Met system by gene therapy (adenovirus-mediated NK4 gene) suppresses hepatocellular carcinoma in mice. J Hepatol. 45, 688-95 (2006)
PubMed link      E-mail link

Reference Number: 474
Nakanishi C, Moriuchi A, Ido A, Numata M, Kim ID, Kusumoto K, Hasuike S, Abe H, Nagata K, Akiyama Y, Uto H, Kataoka H, Tsubouchi H. Effect of hepatocyte growth factor on endogenous hepatocarcinogenesis in rats fed a choline-deficient L-amino acid-defined diet. Oncol Rep. 16 25-31 (2006)
PubMed link      E-mail link

Reference Number: 573
Isbert C, Ritz JP, Roggan A, Schuppan D, Ajubi N, Buhr HJ, Hohenberger W, Germer CT. Laser-induced thermotherapy (LITT) elevates mRNA expression of connective tissue growth factor (CTGF) associated with reduced tumor growth of liver metastases compared to hepatic resection. Lasers Surg Med. 39, 42-50 (2007)
PubMed link      E-mail link

Reference Number: 612
Salvi A, Arici B, Portolani N, Giulini SM, De Petro G, Barlati S. In vitro c-met inhibition by antisense RNA and plasmid-based RNAi down-modulates migration and invasion of hepatocellular carcinoma cells. Int J Oncol. 31, 451-60 (2007)
PubMed link      E-mail link

Reference Number: 645
Lee KH, Choi EY, Hyun MS, Jang BI, Kim TN, Lee HJ, Eun JY, Kim HG, Yoon SS, Lee DS, Kim JH, Kim JR. Role of hepatocyte growth factor/c-Met signaling in regulating urokinase plasminogen activator on invasiveness in human hepatocellular carcinoma: a potential therapeutic target. Clin Exp Metastasis. 25, 89-96 (2008)
PubMed link      E-mail link

Reference Number: 838
Bagai R, Fan W, Ma PC. ARQ-197, an oral small-molecule inhibitor of c-Met for the treatment of solid tumors. IDrugs. 13, 404-14 (2010)
PubMed link      E-mail link

Reference Number: 900
Singhal G, Rajeswari MR. Interaction of actinomycin D with promoter element of c-met and its inhibitory effect on the expression of c-Met. J Biomol Struct Dyn. 26, 625-36 (2009)
PubMed link      E-mail link

Reference Number: 1055
Inagaki Y, Qi F, Gao J, Qu X, Hasegawa K, Sugawara Y, Tang W, Kokudo N. Effect of c-Met inhibitor SU11274 on hepatocellular carcinoma cell growth. Biosci Trends. 5, 52-6 (2011)
PubMed link      E-mail link

Reference Number: 1102
You H, Ding W, Dang H, Jiang Y, Rountree CB. c-Met represents a potential therapeutic target for personalized treatment in hepatocellular carcinoma. Hepatology. 54, 879-89 (2011)
PubMed link      E-mail link

Reference Number: 1131
Gao J, Inagaki Y, Song P, Qu X, Kokudo N, Tang W. Targeting c-Met as a promising strategy for the treatment of hepatocellular carcinoma. Pharmacol Res. 65, 23-30 (2012)
PubMed link      E-mail link

Reference Number: 1132
Huynh H, Ong R, Soo KC. Foretinib demonstrates anti-tumor activity and improves overall survival in preclinical models of hepatocellular carcinoma. Angiogenesis. 15, 59-7 (2012)
PubMed link      E-mail link

Reference Number: 1266
Ozen E, Gozukizil A, Erdal E, Uren A, Bottaro DP, Atabey N. Heparin inhibits Hepatocyte Growth Factor induced motility and invasion of hepatocellular carcinoma cells through early growth response protein 1. PLoS One. 7, e42717 (2012)
PubMed link      E-mail link

Reference Number: 1272
Santoro A, Rimassa L, Borbath I, Daniele B, Salvagni S, Van Laethem JL, Van Vlierberghe H, Trojan J, Kolligs FT, Weiss A, Miles S, Gasbarrini A, Lencioni M, Cicalese L, Sherman M, Gridelli C, Buggisch P, Gerken G, Schmid RM, Boni C, Personeni N, Hassoun Z, Abbadessa G, Schwartz B, Von Roemeling R, Lamar ME, Chen Y, Porta C. Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study. Lancet Oncol. 14, 55-63 (2013)
PubMed link      E-mail link

Reference Number: 1302
Trojan J, Zeuzem S. Tivantinib in hepatocellular carcinoma. Expert Opin Investig Drugs. 22, 141-7 (2013)
PubMed link      E-mail link

Reference Number: 1384
Wang K1, Lim HY, Shi S, Lee J, Deng S, Xie T, Zhu Z, Wang Y, Pocalyko D, Yang WJ, Rejto PA, Mao M, Park CK, Xu J. Genomic landscape of copy number aberrations enables the identification of oncogenic drivers in hepatocellular carcinoma. Hepatology. 58, 706-17 (2013)
PubMed link      E-mail link

Reference Number: 1404
Jiang HL1, Jin JZ, Wu D, Xu D, Lin GF, Yu H, Ma DY, Liang J. Celastrol exerts synergistic effects with PHA-665752 and inhibits tumor growth of c-Met-deficient hepatocellular carcinoma in vivo. Mol Biol Rep 40, 4203-9 (2013)
PubMed link      E-mail link

Reference Number: 1491
Chen X, Ding G, Gao Q, Sun J, Zhang Q, Du L, Qiu Z, Wang C, Zheng F, Sun B, Ni J, Feng Z, Zhu J. PLoS One. A human anti-c-Met Fab fragment conjugated with doxorubicin as targeted chemotherapy for hepatocellular carcinoma. PLos One 8, e63093 (2013)
PubMed link      E-mail link

Reference Number: 1527
Giordano S, Columbano A. Met as a therapeutic target in HCC: facts and hopes. J Hepatol. 60, 442-52 (2014)
PubMed link      E-mail link

Reference Number: 1603
Tabernero J, Elez ME, Herranz M, Rico I, Prudkin L, Andreu J, Mateos J, Carreras MJ, Han M, Gifford J, Credi M, Yin W, Agarwal S, Komarnitsky P, Baselga J A pharmacodynamic/pharmacokinetic study of ficlatuzumab in patients with advanced solid tumors and liver metastases. Clin Cancer Res. 20, 2793-804 (2014)
PubMed link      E-mail link

Reference Number: 1631
Xiang Q, Chen W, Ren M, Wang J, Zhang H, Deng DY, Zhang L, Shang C, Chen Y. Cabozantinib suppresses tumor growth and metastasis in hepatocellular carcinoma by a dual blockade of VEGFR2 and MET. Clin Cancer Res. 20, 2959-70 (2014)
PubMed link      E-mail link

Reference Number: 1743
Okusaka T, Aramaki T, Inaba Y, Nakamura S, Morimoto M, Moriguchi M, Sato T, Ikawa Y, Ikeda M, Furuse J. Phase I study of tivantinib in Japanese patients with advanced hepatocellular carcinoma: Distinctive pharmacokinetic profiles from other solid tumors. Cancer Sci. 106, 611-7 (2015)
PubMed link      E-mail link

Reference Number: 1806
García-Vilas JA, Quesada AR, Medina MA. Damnacanthal, a noni anthraquinone, inhibits c-Met and is a potent antitumor compound against Hep G2 human hepatocellular carcinoma cells. Sci Rep. 5, 8021 (2015)
PubMed link      E-mail link

Reference Number: 1807
Kos P, Lächelt U, Herrmann A, Mickler FM, Döblinger M, He D, Krhac Levacic A, Morys S, Bräuchle C, Wagner E. Histidine-rich stabilized polyplexes for cMet-directed tumor-targeted gene transfer. Nanoscale. 7, 5350-62 (2015)
PubMed link      E-mail link

Reference Number: 1826
Zhang B, Zhang X, Zhou T, Liu J. Clinical observation of liver cancer patients treated with axitinib and cabozantinib after failed sorafenib treatment: a case report and literature review. Cancer Biol Ther. 16, 215-8 (2015)
PubMed link      E-mail link

Reference Number: 1857
Steinway SN, Dang H, You H, Rountree CB, Ding W. The EGFR/ErbB3 Pathway Acts as a Compensatory Survival Mechanism upon c-Met Inhibition in Human c-Met Hepatocellular Carcinoma. PLoS One. 10, e0128159 (2015)
PubMed link      E-mail link

Reference Number: 1863
Ha TY, Hwang S, Moon KM, Won YJ, Song GW, Kim N, Tak E, Ryoo BY, Hong HN. Sorafenib inhibits migration and invasion of hepatocellular carcinoma cells through suppression of matrix metalloproteinase expression. Anticancer Res. 35, 1967-76 (2015)
PubMed link      E-mail link

Reference Number: 1880
Jiang X, Feng K, Zhang Y, Li Z, Zhou F, Dou H, Wang T. Sorafenib and DE605, a novel c-Met inhibitor, synergistically suppress hepatocellular carcinoma. Oncotarget. 6, 12340-56 (2015)
PubMed link      E-mail link

Reference Number: 1898
Goyal L, Wadlow RC, Blaszkowsky LS, Wolpin BM, Abrams TA, McCleary NJ, Sheehan S, Sundaram E, Karol MD, Chen J, Zhu AX. A phase I and pharmacokinetic study of ganetespib (STA-9090) in advanced hepatocellular carcinoma. Invest New Drugs. 33, 128-37 (2015)
PubMed link      E-mail link

Reference Number: 1901
Wu JR, Hu CT, You RI, Ma PL, Pan SM, Lee MC, Wu WS. Preclinical trials for prevention of tumor progression of hepatocellular carcinoma by LZ-8 targeting c-Met dependent and independent pathways. PLoS One. 10, e0114495 (2015)
PubMed link      E-mail link

Reference Number: 1905
Zhang B, Zhang X, Zhou T, Liu J. Clinical observation of liver cancer patients treated with axitinib and cabozantinib after failed sorafenib treatment: a case report and literature review. Cancer Biol Ther. 16, 215-8 (2015)
PubMed link      E-mail link

Reviews

Reference Number: 746
Osada S, Yoshida K. Application of biological study for met expression to cancer therapy. Anticancer Agents Med Chem. 10, 58-63 (2010)
PubMed link      E-mail link

Reference Number: 1007
Eder JP, Vande Woude GF, Boerner SA, LoRusso PM. Novel therapeutic inhibitors of the c-Met signaling pathway in cancer. Clin Cancer Res. 15, 2207-14 (2009)
PubMed link      E-mail link

Reference Number: 1193
Zhu AX. Molecularly targeted therapy for advanced hepatocellular carcinoma in 2012: current status and future perspectives. Semin Oncol. 39, 493-502 (2012)
PubMed link      E-mail link

Reference Number: 1357
Goyal L1, Muzumdar MD, Zhu AX. Targeting the HGF/c-MET pathway in hepatocellular carcinoma. Clin Cancer Res. 19, 2310-8 (2013)
PubMed link      E-mail link

Reference Number: 1369
Marquardt JU, Thorgeirsson SS. Linking MLL and the HGF-MET signaling pathway in liver cancer. J Clin Invest. 123, 2780-3 (2013)
PubMed link      E-mail link

Reference Number: 1690
Rota Caremoli E, Labianca R. Tivantinib: critical review with a focus on hepatocellular carcinoma. Expert Opin Investig Drugs. 23, 1563-74 (2014)
PubMed link      E-mail link

Reference Number: 1789
Johnson PJ. How do mechanisms of hepatocarcinogenesis (HBV, HCV, and NASH) affect our understanding and approach to HCC? Am Soc Clin Oncol Educ Book. (2013)
PubMed link      E-mail link

Reference Number: 1855
Choi KJ, Baik IH, Ye SK, Lee YH. Molecular Targeted Therapy for Hepatocellular Carcinoma: Present Status and Future Directions. Biol Pharm Bull. 38, 986-91 (2015)
PubMed link      E-mail link

Reference Number: 1856
Qi XS, Guo XZ, Han GH, Li HY, Chen J. MET inhibitors for treatment of advanced hepatocellular carcinoma: A review. World J Gastroenterol. 21, 5445-53 (2015)
PubMed link      E-mail link